Published in Biochem J on August 15, 2010
The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? Clin Proteomics (2011) 1.50
ADAM12 transmembrane and secreted isoforms promote breast tumor growth: a distinct role for ADAM12-S protein in tumor metastasis. J Biol Chem (2011) 0.99
ADAM12 produced by tumor cells rather than stromal cells accelerates breast tumor progression. Mol Cancer Res (2011) 0.99
ADAM9 inhibition increases membrane activity of ADAM10 and controls α-secretase processing of amyloid precursor protein. J Biol Chem (2011) 0.92
A disintegrin and metalloproteinase-12 (ADAM12): function, roles in disease progression, and clinical implications. Biochim Biophys Acta (2013) 0.86
Matrix metalloproteinase-10/TIMP-2 structure and analyses define conserved core interactions and diverse exosite interactions in MMP/TIMP complexes. PLoS One (2013) 0.84
Impact of proteolytic enzymes in colorectal cancer development and progression. World J Gastroenterol (2014) 0.83
Targeting autocrine HB-EGF signaling with specific ADAM12 inhibition using recombinant ADAM12 prodomain. Sci Rep (2015) 0.79
Development of high-affinity and high-specificity inhibitors of metalloproteinase 14 through computational design and directed evolution. J Biol Chem (2017) 0.76
Fine Tuning Cell Migration by a Disintegrin and Metalloproteinases. Mediators Inflamm (2017) 0.75
Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders. Prog Mol Biol Transl Sci (2017) 0.75
Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res (2006) 8.26
The kinetics of reversible tight-binding inhibition. Methods Enzymol (1979) 4.13
Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov (2007) 3.36
The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer (2008) 2.90
TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem (2001) 2.58
Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol Biol Cell (2006) 2.43
Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer (2006) 2.20
The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett (2000) 2.03
ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun (2000) 1.90
A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo. J Biol Chem (1998) 1.70
Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme. Proc Natl Acad Sci U S A (1998) 1.70
Remarkable roles of proteolysis on and beyond the cell surface. Curr Opin Cell Biol (2000) 1.67
Phenotypic analysis of Meltrin alpha (ADAM12)-deficient mice: involvement of Meltrin alpha in adipogenesis and myogenesis. Mol Cell Biol (2003) 1.47
Cellular roles of ADAM12 in health and disease. Int J Biochem Cell Biol (2008) 1.46
Specific sequence elements are required for the expression of functional tumor necrosis factor-alpha-converting enzyme (TACE). J Biol Chem (1999) 1.41
Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening. Anal Biochem (2007) 1.35
Identification of the (183)RWTNNFREY(191) region as a critical segment of matrix metalloproteinase 1 for the expression of collagenolytic activity. J Biol Chem (2000) 1.32
Proteolytic processing of delta-like 1 by ADAM proteases. J Biol Chem (2006) 1.21
Structural determinants of the ADAM inhibition by TIMP-3: crystal structure of the TACE-N-TIMP-3 complex. J Mol Biol (2008) 1.18
Folding and characterization of the amino-terminal domain of human tissue inhibitor of metalloproteinases-1 (TIMP-1) expressed at high yield in E. coli. FEBS Lett (1996) 1.16
ADAMs, a disintegrin and metalloproteinases, mediate shedding of oxytocinase. Biochem Biophys Res Commun (2004) 1.16
Threonine 98, the pivotal residue of tissue inhibitor of metalloproteinases (TIMP)-1 in metalloproteinase recognition. J Biol Chem (2004) 1.03
Regulation of ADAM12 cell-surface expression by protein kinase C epsilon. J Biol Chem (2004) 1.03
The C-terminal domains of TACE weaken the inhibitory action of N-TIMP-3. FEBS Lett (2002) 1.02
Unveiling the surface epitopes that render tissue inhibitor of metalloproteinase-1 inactive against membrane type 1-matrix metalloproteinase. J Biol Chem (2003) 1.02
Catalytic properties of ADAM12 and its domain deletion mutants. Biochemistry (2007) 1.01
Total conversion of tissue inhibitor of metalloproteinase (TIMP) for specific metalloproteinase targeting: fine-tuning TIMP-4 for optimal inhibition of tumor necrosis factor-{alpha}-converting enzyme. J Biol Chem (2005) 1.01
Engineering N-terminal domain of tissue inhibitor of metalloproteinase (TIMP)-3 to be a better inhibitor against tumour necrosis factor-alpha-converting enzyme. Biochem J (2002) 0.96
ADAM12 is a four-leafed clover: the excised prodomain remains bound to the mature enzyme. J Biol Chem (2006) 0.95
E. coli expression of TIMP-4 and comparative kinetic studies with TIMP-1 and TIMP-2: insights into the interactions of TIMPs and matrix metalloproteinase 2 (gelatinase A). Biochemistry (2002) 0.95
Targeting ADAM12 in human disease: head, body or tail? Curr Pharm Des (2009) 0.95
ADAM12 localizes with c-Src to actin-rich structures at the cell periphery and regulates Src kinase activity. Exp Cell Res (2009) 0.94
Delineating the molecular basis of the inactivity of tissue inhibitor of metalloproteinase-2 against tumor necrosis factor-alpha-converting enzyme. J Biol Chem (2004) 0.92
The isolated N-terminal domains of TIMP-1 and TIMP-3 are insufficient for ADAM10 inhibition. Biochem J (2008) 0.89
Mapping and characterization of the functional epitopes of tissue inhibitor of metalloproteinases (TIMP)-3 using TIMP-1 as the scaffold: a new frontier in TIMP engineering. Protein Sci (2002) 0.85
MT1-MMP shedding involves an ADAM and is independent of its localization in lipid rafts. Biochem Biophys Res Commun (2006) 0.81
Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res (2003) 13.22
Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res (2006) 8.26
Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci (2002) 4.23
A simplified laminin nomenclature. Matrix Biol (2005) 3.81
The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta (2010) 3.33
A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med (2003) 3.20
Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem (2002) 2.88
Collagenase unwinds triple-helical collagen prior to peptide bond hydrolysis. EMBO J (2004) 2.58
Progress in matrix metalloproteinase research. Mol Aspects Med (2008) 2.51
Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol Biol Cell (2006) 2.43
RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J (2006) 2.34
Dwarfism and impaired gut development in insulin-like growth factor II mRNA-binding protein 1-deficient mice. Mol Cell Biol (2004) 2.08
ERK-mediated phosphorylation of Thr735 in TNFalpha-converting enzyme and its potential role in TACE protein trafficking. J Cell Sci (2005) 1.99
Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. Biochem J (2010) 1.93
Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing. J Biol Chem (2003) 1.87
Cytokine stimulated vascular cell adhesion molecule-1 (VCAM-1) ectodomain release is regulated by TIMP-3. Cardiovasc Res (2005) 1.77
Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? Nat Clin Pract Rheumatol (2008) 1.75
Proteases involved in cartilage matrix degradation in osteoarthritis. Biochim Biophys Acta (2011) 1.73
ADAM12 in human liver cancers: TGF-beta-regulated expression in stellate cells is associated with matrix remodeling. Hepatology (2003) 1.70
Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). J Cell Sci (2002) 1.69
Membrane type I-matrix metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface. J Cell Sci (2003) 1.68
Proteolytic activities of human ADAMTS-5: comparative studies with ADAMTS-4. J Biol Chem (2007) 1.66
Matrix metalloproteinases in cancer. Essays Biochem (2002) 1.65
Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). J Biol Chem (2005) 1.59
ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. Biochem Biophys Res Commun (2002) 1.55
ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem (2004) 1.51
The roles of substrate thermal stability and P2 and P1' subsite identity on matrix metalloproteinase triple-helical peptidase activity and collagen specificity. J Biol Chem (2006) 1.49
Structural insights into triple-helical collagen cleavage by matrix metalloproteinase 1. Proc Natl Acad Sci U S A (2012) 1.46
Cellular roles of ADAM12 in health and disease. Int J Biochem Cell Biol (2008) 1.46
Matrix metalloproteinases in disease and repair processes in the anterior segment. Surv Ophthalmol (2002) 1.41
Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene (2003) 1.40
The disintegrin and metalloproteinase ADAM12 contributes to TGF-beta signaling through interaction with the type II receptor. J Cell Biol (2007) 1.38
Individual Timp deficiencies differentially impact pro-MMP-2 activation. J Biol Chem (2006) 1.34
PINCH1 regulates cell-matrix and cell-cell adhesions, cell polarity and cell survival during the peri-implantation stage. J Cell Sci (2005) 1.34
Evidence for a critical role of the tumor necrosis factor alpha convertase (TACE) in ectodomain shedding of the p75 neurotrophin receptor (p75NTR). J Biol Chem (2003) 1.32
Calcium pentosan polysulfate is a multifaceted exosite inhibitor of aggrecanases. FASEB J (2008) 1.32
Molecular mechanism of type I collagen homotrimer resistance to mammalian collagenases. J Biol Chem (2010) 1.30
X-ray structure of human proMMP-1: new insights into procollagenase activation and collagen binding. J Biol Chem (2004) 1.30
The new frontier in muscular dystrophy research: booster genes. FASEB J (2003) 1.29
Molecular profiling of ADAM12 in human bladder cancer. Clin Cancer Res (2006) 1.26
Carcinomas contain a matrix metalloproteinase-resistant isoform of type I collagen exerting selective support to invasion. Cancer Res (2010) 1.26
Human diabetic corneas preserve wound healing, basement membrane, integrin and MMP-10 differences from normal corneas in organ culture. Exp Eye Res (2003) 1.26
Cell surface collagenolysis requires homodimerization of the membrane-bound collagenase MT1-MMP. Mol Biol Cell (2006) 1.26
Cross-domain inhibition of TACE ectodomain. Proc Natl Acad Sci U S A (2011) 1.26
Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia. Obstet Gynecol (2005) 1.26
A role for ADAM12 in breast tumor progression and stromal cell apoptosis. Cancer Res (2005) 1.24
Src-mediated tyrosine phosphorylation of caveolin-1 induces its association with membrane type 1 matrix metalloproteinase. J Biol Chem (2004) 1.24
Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res (2002) 1.23
Membrane-type 1-matrix metalloproteinase regulates intracellular adhesion molecule-1 (ICAM-1)-mediated monocyte transmigration. J Biol Chem (2007) 1.22
Selective hydrolysis of triple-helical substrates by matrix metalloproteinase-2 and -9. J Biol Chem (2003) 1.22
Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. J Biol Chem (2002) 1.22
Beringian paleoecology inferred from permafrost-preserved fungal DNA. Appl Environ Microbiol (2005) 1.22
The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. J Allergy Clin Immunol (2008) 1.21
Tissue inhibitor of metalloproteinases-1 promotes liver metastasis by induction of hepatocyte growth factor signaling. Cancer Res (2007) 1.21
ADAM12 induces actin cytoskeleton and extracellular matrix reorganization during early adipocyte differentiation by regulating beta1 integrin function. J Cell Sci (2003) 1.21
Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer. Reproduction (2005) 1.21
Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol (2009) 1.20
Crystal structure of an active form of human MMP-1. J Mol Biol (2006) 1.20
Matrix metalloproteinase triple-helical peptidase activities are differentially regulated by substrate stability. Biochemistry (2004) 1.20
Low density lipoprotein receptor-related protein mediates endocytic clearance of pro-MMP-2.TIMP-2 complex through a thrombospondin-independent mechanism. J Biol Chem (2004) 1.20
Selenoprotein N: an endoplasmic reticulum glycoprotein with an early developmental expression pattern. Hum Mol Genet (2003) 1.18
Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J Biol Chem (2004) 1.18
ADAM 12 protease induces adipogenesis in transgenic mice. Am J Pathol (2002) 1.17
ADAM12/syndecan-4 signaling promotes beta 1 integrin-dependent cell spreading through protein kinase Calpha and RhoA. J Biol Chem (2002) 1.16
Fibroblast growth factor receptor 1 is principally responsible for fibroblast growth factor 2-induced catabolic activities in human articular chondrocytes. Arthritis Res Ther (2011) 1.15
Functional differences of the catalytic and non-catalytic domains in human ADAMTS-4 and ADAMTS-5 in aggrecanolytic activity. J Biol Chem (2007) 1.14
Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. Am J Pathol (2005) 1.14
The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett (2002) 1.13
Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 rgulates pro-MMP-2 activation. J Biol Chem (2003) 1.13
TIMP-3 inhibits the procollagen N-proteinase ADAMTS-2. Biochem J (2006) 1.13
Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Biol Chem (2010) 1.13
Increased matrix metalloproteinase-13 production with aging by human articular chondrocytes in response to catabolic stimuli. J Gerontol A Biol Sci Med Sci (2005) 1.13
Temporal and spatial expression of matrix metalloproteinases during wound healing of human corneal tissue. Exp Eye Res (2003) 1.13
A heterogeneous in vitro three dimensional model of tumour-stroma interactions regulating sprouting angiogenesis. PLoS One (2012) 1.12
Involvement of the serine/threonine p70S6 kinase in TGF-beta1-induced ADAM12 expression in cultured human hepatic stellate cells. J Hepatol (2005) 1.12
Matrix metalloproteinase 1 interacts with neuronal integrins and stimulates dephosphorylation of Akt. J Biol Chem (2003) 1.11
Membrane type 1 matrix metalloproteinase is a crucial promoter of synovial invasion in human rheumatoid arthritis. Arthritis Rheum (2009) 1.11
Activation of membrane-type matrix metalloproteinase 3 zymogen by the proprotein convertase furin in the trans-Golgi network. Cancer Res (2002) 1.09
Identification of the extracellular matrix (ECM) binding motifs of tissue inhibitor of metalloproteinases (TIMP)-3 and effective transfer to TIMP-1. J Biol Chem (2007) 1.09
TIMP-3 inhibits aggrecanase-mediated glycosaminoglycan release from cartilage explants stimulated by catabolic factors. FEBS Lett (2003) 1.08
ADAM12 and alpha9beta1 integrin are instrumental in human myogenic cell differentiation. Mol Biol Cell (2004) 1.08
Matrix metalloproteinase expression and function during fin regeneration in zebrafish: analysis of MT1-MMP, MMP2 and TIMP2. Matrix Biol (2005) 1.07
Distinct roles of dopamine and subthalamic nucleus in learning and probabilistic decision making. Brain (2012) 1.07
Palmitoylation at Cys574 is essential for MT1-MMP to promote cell migration. FASEB J (2005) 1.07
The intrinsic protein flexibility of endogenous protease inhibitor TIMP-1 controls its binding interface and affects its function. Biochemistry (2010) 1.06
Reactive site mutations in tissue inhibitor of metalloproteinase-3 disrupt inhibition of matrix metalloproteinases but not tumor necrosis factor-alpha-converting enzyme. J Biol Chem (2005) 1.05
Membrane-type 4 matrix metalloproteinase promotes breast cancer growth and metastases. Cancer Res (2006) 1.04
Phosphorylation-dependent interactions between ADAM15 cytoplasmic domain and Src family protein-tyrosine kinases. J Biol Chem (2001) 1.04
ADAM12: a novel first-trimester maternal serum marker for Down syndrome. Prenat Diagn (2003) 1.04
Cell cholesterol modulates metalloproteinase-dependent shedding of low-density lipoprotein receptor-related protein-1 (LRP-1) and clearance function. FASEB J (2011) 1.03
Threonine 98, the pivotal residue of tissue inhibitor of metalloproteinases (TIMP)-1 in metalloproteinase recognition. J Biol Chem (2004) 1.03
Regulation of ADAM12 cell-surface expression by protein kinase C epsilon. J Biol Chem (2004) 1.03
ADAM12 alleviates the skeletal muscle pathology in mdx dystrophic mice. Am J Pathol (2002) 1.03
Localizing matrix metalloproteinase activities in the pericellular environment. FEBS J (2010) 1.03
Unveiling the surface epitopes that render tissue inhibitor of metalloproteinase-1 inactive against membrane type 1-matrix metalloproteinase. J Biol Chem (2003) 1.02
The C-terminal domains of TACE weaken the inhibitory action of N-TIMP-3. FEBS Lett (2002) 1.02